Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Peng, Li ^a   Bian, Xiu Wu ^b   Li, Di Kang ^a   Xu, Chuan ^b,c   Wang, Guang Ming ^d   Xia, Qing You ^a   Xiong, Qing ^a  

^a SOUTHWEST UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c CHENGDU MILITARY GENERAL HOSPITAL   (China)

^d DALI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR PROTEIN;

CARCINOGENESIS; CASE CONTROL STUDY; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC DATABASE; GENETICS; HUMAN; METABOLISM; NEOPLASM; PROCEDURES; REPRODUCIBILITY; SEQUENCE ANALYSIS;

CARCINOGENESIS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, RNA;

EID: 84940193058     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13413     Document Type: Article

References (179)

1. Hudson, T. J. et al. International network of cancer genome projects. Nature 464, 993-998 (2010).
2. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
3. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3, 246-259 (2013).
4. Tamborero, D. et al. Comprehensive identifcation of mutational cancer driver genes across 12 tumor types. Sci Rep 3, 2650; doi: 10.1038/srep02650 (2013).
5. Abaan, O. D. et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res 73, 4372-4382 (2013).
6. Cheng, W. Y., Ou Yang, T. H. & Anastassiou, D. Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol 9, e1002920; doi: 10.1371/journal.pcbi.1002920 (2013).
7. Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10, 57-63 (2009).
8. Pharoah, P. D., Dunning, A. M., Ponder, B. A. & Easton, D. F. Association studies for fnding cancer-susceptibility genetic variants. Nat Rev Cancer 4, 850-860 (2004).
9. Loeb, K. R. & Loeb, L. A. Signifcance of multiple mutations in cancer. Carcinogenesis 21, 379-385 (2000).
10. Banno, K. et al. Epimutation and cancer: a new carcinogenic mechanism of Lynch syndrome (Review). Int J Oncol 41, 793-797 (2012).
11. Tomlinson, I. P., Novelli, M. R. & Bodmer, W. F. The mutation rate and cancer. Proc Natl Acad Sci USA 93, 14800-14803 (1996).
12. Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719-724 (2009).
13. Gibson, G. Cancer: Directions for the drivers. Nature 512, 31-32 (2014).
14. Bashashati, A. et al. DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. Genome Biol 13, R124; doi: 10.1186/gb-2012-13-12-r124 (2012).
15. Khaitovich, P., Enard, W., Lachmann, M. & Paabo, S. Evolution of primate gene expression. Nat Rev Genet 7, 693-702 (2006).
16. Williams, G. H. & Stoeber, K. The cell cycle and cancer. J Pathol 226, 352-364 (2012).
17. Collins, K., Jacks, T. & Pavletich, N. P. The cell cycle and cancer. Proc Natl Acad Sci USA 94, 2776-2778 (1997).
18. Hartwell, L. H. & Kastan, M. B. Cell cycle control and cancer. Science 266, 1821-1828 (1994).
19. Negrini, S., Gorgoulis, V. G. & Halazonetis, T. D. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11, 220-228 (2010).
20. Sen, S. Aneuploidy and cancer. Curr Opin Oncol 12, 82-88 (2000).
21. Gordon, D. J., Resio, B. & Pellman, D. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 13, 189-203 (2012).
22. Hung, P. F. et al. The motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinoma. PLoS One 8, e61664; doi: 10.1371/journal.pone.0061664 (2013).
23. Liu, X., Gong, H. & Huang, K. Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci 104, 651-656 (2013).
24. de Azambuja, E. et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer 96, 1504-1513 (2007).
25. Tawfk, K., Kimler, B. F., Davis, M. K., Fan, F. & Tawfk, O. Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically signifcant. Hum Pathol 44, 39-46 (2013).
26. Liang, Z. et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 8, 363; doi: 10.1186/1471-2407-8-363 (2008).
27. Arriola, E. et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 88, 491-503 (2008).
28. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100, 11606-11611 (2003).
29. Chase, A. & Cross, N. C. Aberrations of EZH2 in cancer. Clin Cancer Res 17, 2613-2618 (2011).
30. Lee, D. F. et al. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell 11, 179-194 (2012).
31. Chou, C. H. et al. Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer. Cancer Res 73, 953-966 (2013).
32. Zhu, J., Abbruzzese, J. L., Izzo, J., Hittelman, W. N. & Li, D. AURKA amplifcation, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet 159, 10-17 (2005).
33. Nassar, A., Lawson, D., Cotsonis, G. & Cohen, C. Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol 16, 113-120 (2008).
34. Boidot, R. et al. The expression of BIRC5 is correlated with loss of specifc chromosomal regions in breast carcinomas. Genes Chromosomes Cancer 47, 299-308 (2008).
35. Wang, C., Zheng, X., Shen, C. & Shi, Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res 31, 58; doi: 10.1186/1756-9966-31-58 (2012).
36. Alegre, M. M., Robison, R. A. & O'Neill, K. L. Tymidine Kinase 1: A Universal Marker for Cancer. Cancer and Clinical Oncology 2, 159-167 (2013).
37. Alegre, M. M., Robison, R. A. & O'Neill, K. L. Tymidine kinase 1 upregulation is an early event in breast tumor formation. J Oncol 2012, 575647; doi: 10.1155/2012/575647 (2012).
38. Degenhardt, Y. & Lampkin, T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res 16, 384-389 (2010).
39. Weiss, L. & Eferth, T. Polo-like kinase 1 as target for cancer therapy. Exp Hematol Oncol 1, 38; doi: 10.1186/2162-3619-1-38 (2012).
40. Hu, K., Law, J. H., Fotovati, A. & Dunn, S. E. Small interfering RNA library screen identifed polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. Breast Cancer Res 14, R22; doi: 10.1186/bcr3107 (2012).
41. Lord, C. J. & Ashworth, A. RAD51, BRCA2 and DNA repair: a partial resolution. Nat Struct Mol Biol 14, 461-462 (2007).
42. Nagathihalli, N. S. & Nagaraju, G. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta 1816, 209-218 (2011).
43. Tilghman, J. et al. HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells. Cancer Res 74, 3168-3179 (2014).
44. Pujana, M. A. et al. Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 39, 1338-1349 (2007).
45. Suzuki, T. et al. Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 98, 644-651 (2007).
46. Hassan, K. A. et al. Clinical signifcance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin Cancer Res 7, 2458-2462 (2001).
47. Hu, F. et al. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Oncogene 29, 5464-5474 (2010).
48. Shih, M. C. et al. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene 31, 2389-2400 (2012).
49. Li, T., Xue, H., Guo, Y. & Guo, K. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer. Oncol Rep 31, 1825-1831 (2014).
50. D'Andrea, A. D. & Grompe, M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3, 23-34 (2003).
51. Wang, W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8, 735-748 (2007).
52. Rafnar, T. et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet 43, 1104-1107 (2011).
53. Seal, S. et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38, 1239-1241 (2006).
54. De Nicolo, A. et al. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res 14, 4672-4680 (2008).
55. Kim, J. S., Kim, E. J., Oh, J. S., Park, I. C. & Hwang, S. G. CIP2A modulates cell-cycle progression in human cancer cells by regulating the stability and activity of Plk1. Cancer Res 73, 6667-6678 (2013).
56. Liu, N. et al. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol Cancer 13, 111; doi: 10.1186/1476-4598-13-111 (2014).
57. Vaarala, M. H., Vaisanen, M. R. & Ristimaki, A. CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 29, 136; doi: 10.1186/1756-9966-29-136 (2010).
58. Zhao, X. et al. Interruption of cenph causes mitotic failure and embryonic death, and its haploinsufciency suppresses cancer in zebrafsh. J Biol Chem 285, 27924-27934 (2010).
59. Liao, W. T. et al. Centromere protein H is a novel prognostic marker for nasopharyngeal carcinoma progression and overall patient survival. Clin Cancer Res 13, 508-514 (2007).
60. Liao, W. T. et al. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer 115, 1507-1517 (2009).
61. Liao, W. T. et al. Overexpression of centromere protein H is signifcantly associated with breast cancer progression and overall patient survival. Chin J Cancer 30, 627-637 (2011).
62. Potemski, P. et al. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res 25, 59-64 (2006).
63. Sieuwerts, A. M. et al. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients. Clin Cancer Res 12, 3319-3328 (2006).
64. Nakayama, N. et al. Gene amplifcation CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116, 2621-2634 (2010).
65. Gonzalez, S. et al. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 440, 702-706 (2006).
66. Liu, Y., Gong, Z., Sun, L. & Li, X. FOXM1 and androgen receptor co-regulate CDC6 gene transcription and DNA replication in prostate cancer cells. Biochim Biophys Acta 1839, 297-305 (2014).
67. Robles, L. D. et al. Down-regulation of Cdc6, a cell cycle regulatory gene, in prostate cancer. J Biol Chem 277, 25431-25438 (2002).
68. Endo-Munoz, L. et al. E2F7 can regulate proliferation, diferentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation. Cancer Res 69, 1800-1808 (2009).
69. Carvajal, L. A., Hamard, P. J., Tonnessen, C. & Manfredi, J. J. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes Dev 26, 1533-1545 (2012).
70. Chen, H. Z., Tsai, S. Y. & Leone, G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 9, 785-797 (2009).
71. Mudbhary, R. et al. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell 25, 196-209 (2014).
72. Raychaudhuri, P. & Park, H. J. FoxM1: a master regulator of tumor metastasis. Cancer Res 71, 4329-4333 (2011).
73. Lokody, I. Signalling: FOXM1 and CENPF: co-pilots driving prostate cancer. Nat Rev Cancer 14, 450-451 (2014).
74. Halasi, M. & Gartel, A. L. Targeting FOXM1 in cancer. Biochem Pharmacol 85, 644-652 (2013).
75. Koumarianou, A. et al. Prognostic Markers in Early-stage Colorectal Cancer: Signifcance of TYMS mRNA Expression. Anticancer Res 34, 4949-4962 (2014).
76. Conradi, L. C. et al. Tymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment. Ann Surg Oncol 18, 2442-2452 (2011).
77. Hsu, N. Y. et al. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. Anticancer Res 31, 3475-3481 (2011).
78. Putluri, N. et al. Pathway-centric integrative analysis identifes RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia 16, 390-402 (2014).
79. Zhang, K. et al. Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer 8, 11; doi: 10.1186/1476-4598-8-11 (2009).
80. Sun, W., Yao, L., Jiang, B., Guo, L. & Wang, Q. Spindle and kinetochore-associated protein 1 is overexpressed in gastric cancer and modulates cell growth. Mol Cell Biochem 391, 167-174 (2014).
81. Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA 98, 5043-5048 (2001).
82. Lin, H. K. et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464, 374-379 (2010).
83. Wang, Z. et al. Skp2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta 1825, 11-17 (2012).
84. Jordheim, L. P., Seve, P., Tredan, O. & Dumontet, C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 12, 693-702 (2011).
85. Ceppi, P. et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17, 1818-1825 (2006).
86. Agarwal, S. et al. Mahanine restores RASSF1A expression by down-regulating DNMT1 and DNMT3B in prostate cancer cells. Mol Cancer 12, 99; doi: 10.1186/1476-4598-12-99 (2013).
87. Robert, M. F. et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33, 61-65 (2003).
88. Li, A., Omura, N., Hong, S. M. & Goggins, M. Pancreatic cancer DNMT1 expression and sensitivity to DNMT1 inhibitors. Cancer Biol Ter 9, 321-329 (2010).
89. Kullmann, K., Deryal, M., Ong, M. F., Schmidt, W. & Mahlknecht, U. DNMT1 genetic polymorphisms afect breast cancer risk in the central European Caucasian population. Clin Epigenetics 5, 7; doi: 10.1186/1868-7083-5-7 (2013).
90. den Hollander, J. et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116, 1498-1505 (2010).
91. Morozova, O. et al. System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clin Cancer Res 16, 4572-4582 (2010).
92. Addepalli, M. K. et al. RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efcacy in prostate tumor regression. Gene Ter 17, 352-359 (2010).
93. Wagner, K. W. et al. Overexpression, genomic amplifcation and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene 23, 6621-6629 (2004).
94. Pallante, P. et al. UbcH10 overexpression in human lung carcinomas and its correlation with EGFR and p53 mutational status. Eur J Cancer 49, 1117-1126 (2013).
95. Fujita, T. et al. Clinicopathological relevance of UbcH10 in breast cancer. Cancer Sci 100, 238-248 (2009).
96. Rhee, I. et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 416, 552-556 (2002).
97. Subramaniam, D., Tombre, R., Dhar, A. & Anant, S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol 4, 80; doi: 10.3389/fonc.2014.00080 (2014).
98. Robertson, K. D. DNA methylation, methyltransferases, and cancer. Oncogene 20, 3139-3155 (2001).
99. Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7, 249-262 (2001).
100. Silveyra, P., DiAngelo, S. L. & Floros, J. An 11-nt sequence polymorphism at the 3'UTR of human SFTPA1 and SFTPA2 gene variants diferentially afect gene expression levels and miRNA regulation in cell culture. Am J Physiol Lung Cell Mol Physiol 307, L106-119 (2014).
101. Grageda, M., Silveyra, P., Tomas, N. J., DiAngelo, S. L. & Floros, J. DNA methylation profile and expression of surfactant protein A2 gene in lung cancer. Exp Lung Res 41, 93-102 (2015).
102. Wang, Y. et al. Genetic deffects in surfactant protein A2 are associated with pulmonary fbrosis and lung cancer. Am J Hum Genet 84, 52-59 (2009).
103. Lin, Z. et al. DNA methylation markers of surfactant proteins in lung cancer. Int J Oncol 31, 181-191 (2007).
104. Maitra, M., Cano, C. A. & Garcia, C. K. Mutant surfactant A2 proteins associated with familial pulmonary fbrosis and lung cancer induce TGF-beta1 secretion. Proc Natl Acad Sci USA 109, 21064-21069 (2012).
105. Maitra, M., Wang, Y., Gerard, R. D., Mendelson, C. R. & Garcia, C. K. Surfactant protein A2 mutations associated with pulmonary fbrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem 285, 22103-22113 (2010).
106. Choi, E. H., Ehrmantraut, M., Foster, C. B., Moss, J. & Chanock, S. J. Association of common haplotypes of surfactant protein A1 and A2 (SFTPA1 and SFTPA2) genes with severity of lung disease in cystic fbrosis. Pediatr Pulmonol 41, 255-262 (2006).
107. Heinrich, S., Hartl, D. & Griese, M. Surfactant protein A-from genes to human lung diseases. Curr Med Chem 13, 3239-3252 (2006).
108. Zhang, Y. et al. Identifcation and examination of a novel 9-bp insert/deletion polymorphism on porcine SFTPA1 exon 2 associated with acute lung injury using an oleic acid-acute lung injury model. Anim Sci J 86, 573-578 (2015).
109. Silveyra, P. & Floros, J. Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury. Front Biosci (Landmark Ed) 17, 407-429 (2012).
110. Deng, J. et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung infammation and tumorigenesis. Cancer Prev Res (Phila) 3, 424-437 (2010).
111. Barta, P. et al. Enhancement of lung tumorigenesis in a Gprc5a Knockout mouse by chronic extrinsic airway infammation. Mol Cancer 11, 4; doi: 10.1186/1476-4598-11-4 (2012).
112. Chen, Y. et al. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor. Cancer Res 70, 8917-8926 (2010).
113. Fujimoto, J. et al. G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent feld and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer. J Torac Oncol 7, 1747-1754 (2012).
114. Kadara, H. et al. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia 12, 499-505 (2010).
115. Ohira, T. et al. WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci USA 100, 10429-10434 (2003).
116. Tennis, M. A., Vanscoyk, M. M., Wilson, L. A., Kelley, N. & Winn, R. A. Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer. PLoS One 7, e32921; doi: 10.1371/journal.pone.0032921 (2012).
117. LaFemina, M. J. et al. Claudin-18 defciency results in alveolar barrier dysfunction and impaired alveologenesis in mice. Am J Respir Cell Mol Biol 51, 550-558 (2014).
118. Micke, P. et al. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer 135, 2206-2214 (2014).
119. Torjussen, T. M. et al. Childhood lung function and the association with beta2-adrenergic receptor haplotypes. Acta Paediatr 102, 727-731 (2013).
120. Marson, F. A., Bertuzzo, C. S., Ribeiro, A. F. & Ribeiro, J. D. Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fbrosis. BMC Pulm Med 12, 50; doi: 10.1186/1471-2466-12-50 (2012).
121. Byers, D. E. et al. Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease. J Clin Invest 123, 3967-3982 (2013).
122. Li, D. et al. IL-33 promotes ST2-dependent lung fbrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice. J Allergy Clin Immunol 134, 1422-1432 (2014).
123. Tanaka, S. et al. Interferon (alpha, beta and omega) receptor 2 is a prognostic biomarker for lung cancer. Pathobiology 79, 24-33 (2012).
124. Shiao, Y. M. et al. Dysregulation of GIMAP genes in non-small cell lung cancer. Lung Cancer 62, 287-294 (2008).
125. di Martino, E., Tomlinson, D. C. & Knowles, M. A. A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Adv Urol 2012, 429213; doi: 10.1155/2012/429213 (2012).
126. Lamont, F. R. et al. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 104, 75-82 (2011).
127. Heinrich, M., Oberbach, A., Schlichting, N., Stolzenburg, J. U. & Neuhaus, J. Cytokine effects on gap junction communication and connexin expression in human bladder smooth muscle cells and suburothelial myofbroblasts. PLoS One 6, e20792; doi: 10.1371/journal.pone.0020792 (2011).
128. Zaravinos, A., Lambrou, G. I., Boulalas, I., Delakas, D. & Spandidos, D. A. Identifcation of common diferentially expressed genes in urinary bladder cancer. PLoS One 6, e18135; doi: 10.1371/journal.pone.0018135 (2011).
129. Hurley, P. J. et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci USA 109, 14977-14982 (2012).
130. Sasaki, Y. et al. p53 negatively regulates the hepatoma growth factor HDGF. Cancer Res 71, 7038-7047 (2011).
131. Chen, S. C. et al. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial-mesenchymal transition. J Pathol 228, 158-169 (2012).
132. Liu, G. & Chen, X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 21, 7195-7204 (2002).
133. Lacroix, M., Toillon, R. A. & Leclercq, G. p53 and breast cancer, an update. Endocr Relat Cancer 13, 293-325 (2006).
134. Yang, N., Mosher, R., Seo, S., Beebe, D. & Friedl, A. Syndecan-1 in breast cancer stroma fbroblasts regulates extracellular matrix fber organization and carcinoma cell motility. Am J Pathol 178, 325-335 (2011).
135. Maeda, T., Desouky, J. & Friedl, A. Syndecan-1 expression by stromal fbroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 25, 1408-1412 (2006).
136. Gascue, C., Katsanis, N. & Badano, J. L. Cystic diseases of the kidney: ciliary dysfunction and cystogenic mechanisms. Pediatr Nephrol 26, 1181-1195 (2011).
137. Bollee, G. et al. Nephronophthisis related to homozygous NPHP1 gene deletion as a cause of chronic renal failure in adults. Nephrol Dial Transplant 21, 2660-2663 (2006).
138. Saunier, S. et al. Characterization of the NPHP1 locus: mutational mechanism involved in deletions in familial juvenile nephronophthisis. Am J Hum Genet 66, 778-789 (2000).
139. Konrad, M. et al. Large homozygous deletions of the 2q13 region are a major cause of juvenile nephronophthisis. Hum Mol Genet 5, 367-371 (1996).
140. Parisi, M. A. et al. The NPHP1 gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome. Am J Hum Genet 75, 82-91 (2004).
141. Furey, T. S. et al. Support vector machine classifcation and validation of cancer tissue samples using microarray expression data. Bioinformatics 16, 906-914 (2000).
142. Zhang, C., Lu, X. & Zhang, X. Signifcance of gene ranking for classifcation of microarray samples. IEEE/ACM Trans Comput Biol Bioinform 3, 312-320 (2006).
143. Saeys, Y., Inza, I. & Larranaga, P. A review of feature selection techniques in bioinformatics. Bioinformatics 23, 2507-2517 (2007).
144. Sharma, A., Imoto, S. & Miyano, S. A top-r feature selection algorithm for microarray gene expression data. IEEE/ACM Trans Comput Biol Bioinform 9, 754-764 (2012).
145. Joachims, T. Making large-Scale SVM Learning Practical. in Advances in Kernel Methods-Support Vector Learning (eds. Schölkopf, B., Burges, C. & Smola, A.) (MIT-Press, 1999).
146. Seo, J. S. et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22, 2109-2119 (2012).
147. Kim, S. K. et al. A nineteen gene-based risk score classifer predicts prognosis of colorectal cancer patients. Mol Oncol 8, 1653-1666 (2014).
148. Yu, K. et al. A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLoS Genet 4, e1000129; doi: 10.1371/journal.pgen.1000129 (2008).
149. Stefens, S. et al. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Virchows Arch 465, 439-444 (2014).
150. Onishi, T., Ohishi, Y., Goto, H., Suzuki, M. & Miyazawa, Y. Papillary renal cell carcinoma: clinicopathological characteristics and evaluation of prognosis in 42 patients. BJU Int 83, 937-943 (1999).
151. Muller, P. A. & Vousden, K. H. p53 mutations in cancer. Nat Cell Biol 15, 2-8 (2013).
152. Karakas, B., Bachman, K. E. & Park, B. H. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 94, 455-459 (2006).
153. Kleinerman, R. A. et al. Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst 92, 2037-2039 (2000).
154. Menendez, D., Inga, A. & Resnick, M. A. The expanding universe of p53 targets. Nat Rev Cancer 9, 724-737 (2009).
155. Leek, J. T. et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 11, 733-739 (2010).
156. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for diferential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
157. Anders, S. & Huber, W. Diferential expression analysis for sequence count data. Genome Biol 11, R106; doi: 10.1186/gb-2010-11-10-r106 (2010).
158. Bodenhofer, U., Kothmeier, A. & Hochreiter, S. APCluster: an R package for afnity propagation clustering. Bioinformatics 27, 2463-2464 (2011).
159. Frey, B. J. & Dueck, D. Clustering by passing messages between data points. Science 315, 972-976 (2007).
160. Xiong, Q., Mukherjee, S. & Furey, T. S. GSAASeqSP: a toolset for gene set association analysis of RNA-Seq data. Sci Rep 4, 6347; doi: 10.1038/srep06347 (2014).
161. Zhang, B., Kirov, S. & Snoddy, J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33, W741-748 (2005).
162. Wang, J., Duncan, D., Shi, Z. & Zhang, B. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res 41, W77-83 (2013).
163. Kanehisa, M. et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 42, D199-205 (2014).
164. Cerami, E. G. et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res 39, D685-690 (2011).
165. Killock, D. Lung cancer: alternative rearrangements-targeting ROS1 in NSCLC. Nat Rev Clin Oncol 11, 624; doi: 10.1038/nrclinonc.2014.180 (2014).
166. Bergethon, K. et al. ROS1 rearrangements defne a unique molecular class of lung cancers. J Clin Oncol 30, 863-870 (2012).
167. Campo, I. et al. A large kindred of pulmonary fbrosis associated with a novel ABCA3 gene variant. Respir Res 15, 43; doi: 10.1186/1465-9921-15-43 (2014).
168. Wambach, J. A. et al. Genotype-phenotype correlations for infants and children with ABCA3 defciency. Am J Respir Crit Care Med 189, 1538-1543 (2014).
169. Agrawal, A. et al. An intronic ABCA3 mutation that is responsible for respiratory disease. Pediatr Res 71, 633-637 (2012).
170. Gower, W. A. et al. Fatal familial lung disease caused by ABCA3 defciency without identifed ABCA3 mutations. J Pediatr 157, 62-68 (2010).
171. Xie, Y. et al. Aquaporin 1 and aquaporin 4 are involved in invasion of lung cancer cells. Clin Lab 58, 75-80 (2012).
172. Warth, A. et al. Loss of aquaporin-4 expression and putative function in non-small cell lung cancer. BMC Cancer 11, 161; doi: 10.1186/1471-2407-11-161 (2011).
173. Yang, Q. et al. STAT3 activation and aberrant ligand-dependent sonic hedgehog signaling in human pulmonary adenocarcinoma. Exp Mol Pathol 93, 227-236 (2012).
174. Zhou, X. et al. Identifcation of a chronic obstructive pulmonary disease genetic determinant that regulates HHIP. Hum Mol Genet 21, 1325-1335 (2012).
175. Li, X. et al. Importance of hedgehog interacting protein and other lung function genes in asthma. J Allergy Clin Immunol 127, 1457-1465 (2011).
176. Jonsson, A. L., Simonsen, U., Hilberg, O. & Bendstrup, E. Pulmonary alveolar microlithiasis: two case reports and review of the literature. Eur Respir Rev 21, 249-256 (2012).
177. Ferreira Francisco, F. A., Pereira e Silva, J. L., Hochhegger, B., Zanetti, G. & Marchiori, E. Pulmonary alveolar microlithiasis. State-of-the-art review. Respir Med 107, 1-9 (2013).
178. Edmiston, J. S. et al. Gene expression profling of peripheral blood leukocytes identifes potential novel biomarkers of chronic obstructive pulmonary disease in current and former smokers. Biomarkers 15, 715-730 (2010).
179. Hawkins, G. A. et al. The IL6R variation Asp(358)Ala is a potential modifer of lung function in subjects with asthma. J Allergy Clin Immunol 130, 510-515 e511 (2012).